Completed PHASE1 INTERVENTIONAL NCT00989872

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers

Sponsor: Enanta Pharmaceuticals, Inc

Conditions Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections

Interventions EDP-322

Updated 6 times since 2017 Last updated: Oct 5, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Methicillin-resistant Staphylococcus Aureus and Skin and Soft Tissue Infections, this trial is completed. The trial is conducted by Enanta Pharmaceuticals, Inc and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Nov 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enanta Pharmaceuticals, Inc

Data source: Enanta Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States